Compare AIN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | PRCT |
|---|---|---|
| Founded | 1895 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1994 | 2021 |
| Metric | AIN | PRCT |
|---|---|---|
| Price | $54.04 | $27.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $60.25 | $35.44 |
| AVG Volume (30 Days) | 291.7K | ★ 2.2M |
| Earning Date | 06-01-2026 | 05-27-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,054,132,000.00 | $308,054,000.00 |
| Revenue This Year | $2.89 | $32.85 |
| Revenue Next Year | N/A | $24.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.29 | ★ 37.22 |
| 52 Week Low | $41.15 | $19.35 |
| 52 Week High | $75.16 | $64.89 |
| Indicator | AIN | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 52.71 |
| Support Level | $52.23 | $19.35 |
| Resistance Level | $60.43 | $29.24 |
| Average True Range (ATR) | 2.02 | 2.19 |
| MACD | -0.61 | 0.39 |
| Stochastic Oscillator | 18.88 | 93.42 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.